Imatinib Tablets

Imatinib tablets are a targeted anticancer therapy formulated as a tyrosine kinase inhibitor that blocks specific proteins involved in cancer cell growth. The formulation enables precise and effective treatment in selected hematological and solid tumors.

• Tyrosine kinase inhibitor targeting BCR-ABL and related pathways
• Inhibits abnormal cell proliferation at the molecular level
• Designed for targeted and long-term cancer management
• Oral dosage form for convenient administration
• Provides consistent and controlled therapeutic response
• Manufactured under stringent cGMP and quality standards

This medication is widely used in oncology for the treatment of certain blood cancers and gastrointestinal tumors. It is prescribed as part of specialized treatment protocols.

• Chronic myeloid leukemia (CML)
• Acute lymphoblastic leukemia (Philadelphia chromosome-positive)
• Gastrointestinal stromal tumors (GIST)
• Myelodysplastic/myeloproliferative disorders
• Other kinase-driven malignancies as per clinical indication

The formulation offers targeted therapy with improved outcomes compared to conventional treatments. It supports long-term disease control and patient convenience.

• Targeted action at the molecular level
• Helps control disease progression effectively
• Oral therapy enhances patient compliance
• Suitable for long-term treatment regimens
• Predictable and reliable therapeutic performance
• Stable formulation suitable for global supply and oncology markets